[go: up one dir, main page]

WO2008101469A3 - Préparation pharmaceutique pour lutter contre des métastases - Google Patents

Préparation pharmaceutique pour lutter contre des métastases Download PDF

Info

Publication number
WO2008101469A3
WO2008101469A3 PCT/DE2008/000264 DE2008000264W WO2008101469A3 WO 2008101469 A3 WO2008101469 A3 WO 2008101469A3 DE 2008000264 W DE2008000264 W DE 2008000264W WO 2008101469 A3 WO2008101469 A3 WO 2008101469A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical preparation
treating metastases
substance
lipids
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2008/000264
Other languages
German (de)
English (en)
Other versions
WO2008101469A2 (fr
Inventor
Reinhardt Zeisig
Iduna Fichtner
Jane Wenzel
Christian Nowak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Publication of WO2008101469A2 publication Critical patent/WO2008101469A2/fr
Publication of WO2008101469A3 publication Critical patent/WO2008101469A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouvelles préparations pharmaceutiques et leur utilisation pour produire des médicaments destinés à lutter contre des métastases, ces médicaments contenant des liposomes. Ces préparations sont des formulations liposomales. Selon l'invention, ces formulations contiennent, outre des substances additives éventuelles, au moins une substance à action antitumorale et au moins une substance à action anticoagulante. Elles se composent en particulier de lipides de base et éventuellement d'autres constituants, tels que des lipides auxiliaires, des stabilisateurs de membranes et des porteurs de charges, et peuvent présenter une surface modifiée améliorant leur efficacité.
PCT/DE2008/000264 2007-02-19 2008-02-14 Préparation pharmaceutique pour lutter contre des métastases Ceased WO2008101469A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007008484.8 2007-02-19
DE102007008484A DE102007008484A1 (de) 2007-02-19 2007-02-19 Pharmazeutische Zubereitung zur Bekämpfung von Metastasen

Publications (2)

Publication Number Publication Date
WO2008101469A2 WO2008101469A2 (fr) 2008-08-28
WO2008101469A3 true WO2008101469A3 (fr) 2009-01-29

Family

ID=39529675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2008/000264 Ceased WO2008101469A2 (fr) 2007-02-19 2008-02-14 Préparation pharmaceutique pour lutter contre des métastases

Country Status (2)

Country Link
DE (1) DE102007008484A1 (fr)
WO (1) WO2008101469A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106541A (zh) * 2015-01-28 2017-08-29 瑞采生技有限公司 用于增强PPARγ表现及核转位之化合物及其医疗用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466716A (en) * 1990-12-31 1995-11-14 The Biomembrane Institute Liposomal trimethylsphingosine
US20050288251A1 (en) * 2004-03-16 2005-12-29 The General Hospital Corporation Treatment and prevention of abnormal cellular proliferation
WO2006024675A1 (fr) * 2004-09-03 2006-03-09 Forschungszentrum Karlsruhe Gmbh Utilisation d'alkylphospholipides pour traiter des tumeurs solides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151360A (en) * 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
EP1839648A3 (fr) * 1998-11-12 2007-11-21 Transave, Inc. Système d'inhalation
ES2185418T3 (es) * 1998-12-04 2003-04-16 Max Delbrueck Centrum Agentes previstos para tratar tumores, basados en liposomas y que contienen tamoxifeno.
WO2002057273A1 (fr) * 2001-01-20 2002-07-25 Trigen Limited Inhibiteurs de la serine protease comprenant un accepteur de liaison hydrogene
WO2002060894A2 (fr) * 2001-01-30 2002-08-08 Bristol-Myers Squibb Company Lactames sulfonamide inhibiteurs de facteur xa
US7081460B2 (en) * 2001-04-09 2006-07-25 Ortho-Mcneil Pharmaceutical, Inc. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
EP1416974A1 (fr) * 2001-08-16 2004-05-12 Bristol-Myers Squibb Pharma Company Composites de liposomes a microspheres de gaz

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466716A (en) * 1990-12-31 1995-11-14 The Biomembrane Institute Liposomal trimethylsphingosine
US20050288251A1 (en) * 2004-03-16 2005-12-29 The General Hospital Corporation Treatment and prevention of abnormal cellular proliferation
WO2006024675A1 (fr) * 2004-09-03 2006-03-09 Forschungszentrum Karlsruhe Gmbh Utilisation d'alkylphospholipides pour traiter des tumeurs solides

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
D. ARNDT ET AL.: "Alkylphospholipid liposomes: preparation, properties and use in cancer research", DRUGS OF TODAY, vol. 34, 1998, pages 83 - 96, XP008059034 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; XP002503801, retrieved from EPO Database accession no. PREV200510270367 *
E. DIAL ET AL.: "Phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit DNA synthesis and the growth of colon cancer cells in vitro.", CANCER CHEMOTER PHARMACOL, vol. 57, 2006, pages 295 - 300, XP019334299 *
H. HAN ET AL.: "In vivo distribution and antitumor activity of heparin stabilized doxorubicin-loaded liposomes", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 313, 2006, pages 181 - 188, XP005353546 *
R. BAZ ET AL.: "Aspirin decreases the thrombotic complications (DVT) of liposomal doxorubicin, vincristine, decreased frequency dexamethasone and thalidomide (DVd-T) treatment of multiple myeloma (MM)", BLOOD, vol. 104, no. 11, 2004, pages 658A - 659A *
R. MOOG ET AL.: "Enhanced in vivo anticancer efficacy of gemcitabine after encapsulation into vesicular phospholipid gels", PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE OF BIOACTIVE MATERIALS, vol. 26, 1999, pages 48 - 48, XP008098661 *
T. CHOU ET AL.: "Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method.", JOURNAL OF BIOSCIENCE AND BIOENGINEERING, vol. 95, no. 4, 2003, pages 405 - 408, XP002503800 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106541A (zh) * 2015-01-28 2017-08-29 瑞采生技有限公司 用于增强PPARγ表现及核转位之化合物及其医疗用途

Also Published As

Publication number Publication date
DE102007008484A1 (de) 2008-08-21
WO2008101469A2 (fr) 2008-08-28

Similar Documents

Publication Publication Date Title
CY1123945T1 (el) Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες
WO2009135190A3 (fr) Particules de phosphate de calcium thérapeutiques et procédés pour les fabriquer et les utiliser
ZA202101465B (en) Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
CY1116075T1 (el) Νεες συνθεσεις λιποσωματων
WO2008063808A3 (fr) Nanostructures amphiphiles peptidiques encapsulées
AU2016343803A8 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP1874793A4 (fr) Administration d'arnsi par compositions lipidiques neutres
WO2010048536A3 (fr) Procédés de préparation de lipides
WO2008042973A3 (fr) Formulations contenant un lipide
WO2017049245A3 (fr) Composés et compositions pour l'administration intracellulaire d'agents thérapeutiques
WO2007064857A3 (fr) Formulation de liposomes amphoteres
WO2008058547A3 (fr) Composition d'alpha-lactalbumine
ATE537263T1 (de) Kationische lipide und verwendungsverfahren
WO2015184256A3 (fr) Lipides biodégradables pour l'administration d'acides nucléiques
EP4481047A3 (fr) Lipides biodégradables pour l'administration d'agents actifs
WO2005063201A3 (fr) Liposomes et compositions liposomales pour la vaccination et l'administration de medicaments
WO2012054500A3 (fr) Compositions pour l'administration de médicaments
WO2011141705A8 (fr) Nouveaux lipides cationiques et procédés d'utilisation de ceux-ci
WO2009047006A3 (fr) Perfectionnements aux ou se rapportant aux liposomes amphotères comprenant des lipides neutres
WO2008017381A8 (fr) Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituée, son procédé de fabrication, médicament contenant ce composé et son utilisation
EP3381445A3 (fr) Formulation aqueuse d'anticorps stabilisée par des antioxydants pour administration parentérale
WO2012021107A3 (fr) Formulation de liposomes pour l'administration d'un médicament dans l'œil
WO2005094783A3 (fr) Liposomes amphoteres a stabilite serique
WO2008097924A3 (fr) Compositions pharmaceutiques comprenant des analogues du dextrométhorphane pour le traitement de troubles neurologiques
WO2013040227A3 (fr) Composés thérapeutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08715489

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08715489

Country of ref document: EP

Kind code of ref document: A2